[1]郭睿,晋建华,任媛,等.99mTc-枸橼酸盐显像鉴别骨转移癌与良性退行性骨病变[J].国际放射医学核医学杂志,2008,32(3):162-164.
　GUO Rui,JIN Jian-hua,REN Yuan,et al.Differentiation of malignant and degenerative benign bone disease using 99mTc-citrate scintigraphy[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(3):162-164.
点击复制

99mTc-枸橼酸盐显像鉴别骨转移癌与良性退行性骨病变(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
32
期数:
2008年第3期
页码:
162-164
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Differentiation of malignant and degenerative benign bone disease using 99mTc-citrate scintigraphy
作者:
郭睿1;  晋建华1;  任媛2;  李思进1;  李险峰1;  张晓娟1
1. 030001 太原, 山西医科大学第一医院核医学科;
2. 030012 太原, 山西省肿瘤医院核医学科
Author(s):
GUO Rui1;  JIN Jian-hua1;  REN Yuan2;  LI Si-jin1;  LI Xian-feng1;  ZHANG Xiao-juan1
1. Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan 030001, China;
2. Department of Nuclear Medicine, Shanxi Tumor Hospital, Taiyuan 030013, China
关键词:
骨肿瘤; 肿瘤转移; 良性退行性骨病; 99m锝-枸橼酸盐; 99m锝-美罗酸盐; 鉴别诊断
Keywords:
Bone neoplasms; Neoplasms mebastasis; Degenerative bone lesions; 99mTc-citrate; 99mTc-medronate; Differential diagnosis
摘要:
目的 探讨99mTc-枸橼酸盐(99mTc-citrate)显像在骨转移癌与良性退行性骨病鉴别诊断中的价值。方法 对99mTc-亚甲基二膦酸盐(99mTc-MDP)骨显像阳性患者39例(92个病灶)在显像后的2~7 d内行99mTc-citrate显像,并分别进行定性及半定量分析,所有患者的临床诊断均经病理学、影像学、临床随访等证实。结果 定性分析:23例(48个病灶)骨转移癌患者的99mTc-citrate显像示72.92%病灶(35/48)呈异常浓聚;16例良性退行性骨病变者99mTc-citrate显像示88.64%病灶(39/44)无异常浓聚。半定量分析:99mTc-citrate显像示48个骨转移灶的病灶与健侧放射性摄取比(RUR)=1.47±0.42,44个良性退行性骨病灶RUR=1.09±0.38,两者相比差异有显著性(t=2.887,P<0.01);而99mTc-MDP显像示48个骨转移灶RUR=1.96±0.25,44个良性退行性骨病灶RUR=1.87±0.21,差异无显著性(t=1.178,P>0.20)。结论 对99mTc-MDP骨显像阳性患者,99mTc-citrate显像在鉴别骨转移癌和良性退行性骨病中具有一定价值。
Abstract:
Objective To differentiate malignant and degenerative benign bone disease using 99mTc-citrate scintigraphy.Methods Thirty-nine patients(92 lesions)with confirmed malignant bone disease or degenerative benign bone disease were studied,for which the results of 99mTc-methylene diphosphonate(99mTc-MDP)scintigraphy were positive.99mTc-citrate seintigraphy was performed within a time interval of 2-7 days after 99mTc-MDP scinfigraphy.Visual analysis and semiquantitative analysis were apphed.Each lesion was scored as malignant or benign,which was independently verified,using conventional techniques (histopathology,X-ray,CT,MRI and clinical follow up).Results In visual analysis of 99mTc-citrate imaging,most malignant lesions(35/48,72.92%)clearly showed high radioactivity accumulation,while most benign lesions(39/44,88.64%)had not obviously visible uptake of 99mTc-citrate.In semiquantitative analysis of 99mTc-citrate image,malignant lesions demonstrated a higher lesion-to-background radioisotope uptake ratio (RUR)than that of benign degenerative lesions(1.47±0.42 vs.1.09±o.38,t=2.887,P<0.01),while RUR of 99mTc-MDP in the two groups is of the same(1.96±0.25 vs.1.87±0.21,t=1.178,P>0.20).Conclusion 99mTc-citrate scintigraphy is a promising method to differentiate malignant from benign degenemfive lesions Seen as areas of increased activity on 99mTc-MDP bone seintigraphy.

参考文献/References:

[1] Sharma R, Mondal A, Bhatnagar A, et al. Differentiation of malignant and degenerative benign bone disease using Tc-99m MDP and Tc-99m citrate scintigraphy[J]. Clin Nucl Med, 1998, 23(11):758-763.
[2] Bhatnagar A, Mishra P, Sharma R, et al.99Tcm-citrate:a new bone imaging radiopharmaceutical[J]. Nucl Med Commun, 1999, 20(11):1067-1076.
[3] Jacobson AF, Stomper PC, Jochelson PC, et al. Association between number and sites of new bone abnormalities and presence of skeletal metastasis in patients with breast cancer[J]. J Nucl Med, 1990, 31(4):387-392.
[4] Fogelman I, Cook G, Israel O, et al. Positron emission tomography and bone metastases[J]. Semin Nucl Med, 2005, 35(2):135-142.
[5] Gayed I, Vu T, JohnsonM, et al. Comparison of bone and 18F-FDG PET in the evaluation of bony metastases in lung cancer[J]. Mol Imaging Biol, 2003, 5(1):26-31.
[6] Ercan MT, Aras T, Unlenen E, et al. 99Tcm-citrate versus 67Ga-citrate for the seintigraphie visualization of inflammatory lesions[J]. Nuel Med Biol, 1993, 20(7):881-887.
[7] 武兆忠,吴波以,林伟,等.99Tcm-MDP、99Tcm(V)-DMSA和99Tcm-Citrate显像对骨组织良恶性疾病鉴别诊断的对比研究[J].核技术,2003,26(8):633-637.
[8] Strobel K, Burger C, Seifert B, et al. Characterization of focal bone lesions in the axial skeleton:performance of planar bone scintigraphy compared with SPECT and SPECT fused with CT[J]. AIR Am J Roentgenol, 2007, 188(5):W467-W474.

相似文献/References:

[1]廖光星,冷志欣,肖国有.前列腺癌骨转移影像诊断方法研究进展[J].国际放射医学核医学杂志,2016,40(6):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
　Liao Guangxing,Leng Zhixin,Xiao Guoyou.Progress of imaging in the diagnosis of bone metastases of prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
[2]周文兰,吴湖炳,韩彦江,等.18F-FDG PET/CT对骨骼孤立性高代谢病灶的初步诊断价值[J].国际放射医学核医学杂志,2015,39(1):14.[doi:10.3760/cma.j.issn.1673-4114.2015.01.005]
　Zhou Wenlan,Wu Hubing,Han Yanjiang,et al.Preliminary study of 18F-FDG PET/CT in the diagnosis of solitary hypermetabolic lesion of bone[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):14.[doi:10.3760/cma.j.issn.1673-4114.2015.01.005]
[3]张胤,陈跃.18F-氟化钠PET/CT诊断肿瘤骨转移应用进展[J].国际放射医学核医学杂志,2015,39(1):96.[doi:10.3760/cma.j.issn.1673-4114.2015.01.020]
　Zhang Yin,Chen Yue.Application progress of 18F-NaF PET/CT in the diagnosis of neoplasm metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):96.[doi:10.3760/cma.j.issn.1673-4114.2015.01.020]
[4]徐金苹,袁德晓,张江虹,等.辐射诱导的外泌体在肿瘤细胞侵袭转移中的作用[J].国际放射医学核医学杂志,2015,39(2):144.[doi:10.3760/cma.j.issn.1673-4114.2015.02.009]
　Xu Jinping,Yuan Dexiao,Zhang Jianghong,et al.The role of radiation-induced exosomes in tumor invasion and metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):144.[doi:10.3760/cma.j.issn.1673-4114.2015.02.009]
[5]刘雪辉,李洪均,于鸿煦.SPECT/CT融合显像对可疑骨转移灶的诊断效能[J].国际放射医学核医学杂志,2015,39(3):201.[doi:10.3760/cma.j.issn.1673-4114.2015.03.003]
　Liu Xuehui,Li Hongjun,Yu Hongxu.Diagnostic efficacy of SPECT/CT fusion imaging in assessing possible bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):201.[doi:10.3760/cma.j.issn.1673-4114.2015.03.003]
[6]桂继琮,刘兴党.镭-223氯化物治疗去势抵抗性前列腺癌骨转移的研究进展[J].国际放射医学核医学杂志,2015,39(3):268.[doi:10.3760/cma.j.issn.1673-4114.2015.03.018]
　Gui Jicong,Liu Xingdang.Development in the study of radium-223 chloride for treating castration-resistant prostate carcinoma with bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):268.[doi:10.3760/cma.j.issn.1673-4114.2015.03.018]
[7]高平,王茜,赵赟赟,等.99Tcm-MDP SPECT/CT显像用于骨肉瘤肺转移的诊断[J].国际放射医学核医学杂志,2014,38(3):148.[doi:10.3760/cma.j.issn.1673-4114.2014.03.002]
　Gao Ping,Wang Qian,Zhao Yunyun,et al.99Tcm-MDP SPECT/CT used in diagnosis of pulmonary metastasis from osteosarcoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):148.[doi:10.3760/cma.j.issn.1673-4114.2014.03.002]
[8]凌彩霞,肖国有.SPECT/CT骨断层显像及在恶性肿瘤骨转移诊断中的临床价值[J].国际放射医学核医学杂志,2014,38(4):275.[doi:10.3760/cma.j.issn.1673-4114.2014.04.016]
　Ling Caixia,Xiao Guoyou.The clinical value of SPECT/CT bone tomography in the diagnosis of malignant tumor metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):275.[doi:10.3760/cma.j.issn.1673-4114.2014.04.016]
[9]王宇峰,刘海娜,张居洋,等.SPECT/CT融合显像对乳腺癌骨转移的诊断价值[J].国际放射医学核医学杂志,2014,38(6):387.[doi:10.3760/cma.j.issn.1673-4114.2014.06.010]
　Wang Yu-feng,Liu Hai-na,Zhang Ju-yang,et al.Clinical value of SPECT/CT fusion imaging in diagnosing metastatic bone lesions in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):387.[doi:10.3760/cma.j.issn.1673-4114.2014.06.010]
[10]赵红光,徐松柏,关锋,等.骶骨脊索瘤伴肺转移18F-FDG PET/CT显像一例[J].国际放射医学核医学杂志,2013,37(2):128.[doi:10.3760/cma.j.issn.1673-4114.2013.02.017]
[11]刘超,邓智勇,刘鹏杰,等.89SrCL2与唑来膦酸联合治疗乳腺癌转移性骨肿瘤的疗效分析[J].国际放射医学核医学杂志,2014,38(5):300.[doi:10.3760/cma.j.issn.1673-4114.2014.05.006]
　Liu Chao,Deng Zhi-yong,Liu Peng-jie,et al.Analysis on the curative effect of combination therapy with zoledronic acid and 89SrCL2 on bone tumor with breast cancer metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):300.[doi:10.3760/cma.j.issn.1673-4114.2014.05.006]
[12]袁超,李卫鹏,胡永全,等.89Sr治疗乳腺癌和前列腺癌多发性骨转移的临床观察[J].国际放射医学核医学杂志,2010,34(4):220.[doi:10.3760/cma.j.issn.1673-4114.2010.04.008]
　YUAN Chao,LI Wei-peng,HU Yong-quan,et al.Clinical observation of 89Sr treatment efficacy of multiple bone metastases in breast and prostate cancer patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):220.[doi:10.3760/cma.j.issn.1673-4114.2010.04.008]
[13]何建华,喻文才.89SrCl2与153Sm-乙二胺四亚甲基膦酸治疗骨转移癌的对比研究[J].国际放射医学核医学杂志,2009,33(2):86.[doi:10.3760/cma.j.issn.1673-4114.2009.02.007]
　HE Jian-hua,YU Wen-cai.Comparison of treatment with 89SrCl2 and 153Sm-ethylenediaminetetramethylene phosphate in metastatic cancers of bone[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(3):86.[doi:10.3760/cma.j.issn.1673-4114.2009.02.007]
[14]叶慧,莫逸,谢爱民,等.18F-氟脱氧葡萄糖PET-CT与99nTc-亚甲基二膦酸盐骨显像诊断转移性骨肿瘤的对比研究[J].国际放射医学核医学杂志,2008,32(3):147.
　YE Hui,MO Yi,XIE Ai-min,et al.Comparison study of 18F-fluorodeoxyglucose PET-CT and 99Tc-methylene phospho-nate bone scan in detecting bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(3):147.
[15]耿峻,吴兴勇,胡德胜,等.前列腺癌48例患者全身核素骨显像的临床价值[J].国际放射医学核医学杂志,2007,31(4):238.
[16]青春,邓候富,贾志云.放射性核素89Sr治疗骨转移癌的新进展[J].国际放射医学核医学杂志,2007,31(3):160.
　QING Chun,DENG Hou-fu,JIA Zhi-yun.The new advances of radionuclide 89Sr in metastatic bone cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(3):160.
[17]王俊起,高硕.PET评价骨转移瘤[J].国际放射医学核医学杂志,2006,30(2):87.
　WANG Jun-qi,GAO Shuo.PET in the evaluation of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(3):87.

备注/Memo

备注/Memo:
收稿日期:2007-09-16。
通讯作者:晋建华(E-mail:jjh1225@126.com)
更新日期/Last Update: 1900-01-01